Microvessel-on-a-chip model for studying ultrasound and microbubble-mediated drug delivery

Abstract (2023)
Author(s)

Bram Meijlink (Erasmus MC)

Inés Beekers (Erasmus MC, Ortec B.V.)

Simone A.G. Langeveld (Erasmus MC)

Kristina Bishard (Mimetas B.V. The Organ-on-Chip Company)

Antonius F.W. van der Steen (TU Delft - ImPhys/Medical Imaging, Erasmus MC, TU Delft - ImPhys/Verweij group)

N. de Jong (Erasmus MC, TU Delft - ImPhys/Verweij group)

Sebastiaan J. Trietsch (Ortec B.V.)

Klazina Kooiman (Erasmus MC)

Research Group
ImPhys/Medical Imaging
More Info
expand_more
Publication Year
2023
Language
English
Research Group
ImPhys/Medical Imaging
Pages (from-to)
143-143
Reuse Rights

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

Abstract

The blood vessel wall creates a barrier which can impair the transport of drugs from the blood to the underlying tissue. Lipid-coated gas microbubbles (diameter 1-10 μm) oscillate upon ultrasound application which can be used to locally enhance vascular permeability. However, the mechanism underlying this effect is poorly understood. Furthermore, it is yet to be discovered what ultrasound settings maximize the treatment outcome. This study aimed to create a microvessel-on-a-chip model to investigate the effects of ultrasound and microbubble treatment on vessel permeability and cell viability. Human microvascular endothelial cells were seeded against an extracellular matrix gel in the Organoplate® 3-lane and cultured for 4 days under bidirectional flow to form a 3D microvascular tube (300×220×2200 μm). The microvessels were treated with αvβ3-targeted microbubbles and 2 MHz ultrasound pulses of 10×10 or 10×1000 cycles, evenly spread over 30 s, and peak negative pressures ranging from 55-480 kPa. Controls included non-treated, microbubbles only, or ultrasound only. Permeability changes were investigated using 150 kDa FITC-dextran dye and fluorescent microscopy for 2 h. Cell viability was assessed using a WST-8 colorimetric assay which measures metabolic activity. Two hours after treatment, vascular permeability was only significantly higher for the microbubble and 480 kPa 10×10 cycles and 350 and 480 kPa 10×1000 cycles ultrasound treatments in comparison to all controls. In addition, within 5 min after treatment only the microbubble and 350 and 480 10×1000 cycles groups showed a clear leakage increase, suggesting an earlier onset of the treatment effect upon the 10×1000 cycles. Furthermore, the plateau of the leakage approached 100% for the 10×1000 cycles with microbubble groups whereas this was ~70% for the 480 kPa 10×10 cycles, indicating that the barrier loss was less with the short cycle’s treatment. The spatial leakage was unevenly distributed over the vessel which suggests that some vessel regions were more affected by the treatment than others. Finally, all treatments did not affect cell viability. These results show the potential of a microvessel-on-a-chip to investigate the mechanism and maximize the outcome of ultrasound and microbubble-mediated drug delivery treatments.

Files

Altex_MPS2_06.pdf
(pdf | 0.512 Mb)
License info not available